Mounjaro (Tirzepatide) History & Development: How This Dual-Action Drug Was Built

Where the Science Behind Mounjaro Actually Started

Tirzepatide did not appear out of nowhere in 2022. Its origin traces back to decades of incretin biology research that started long before Eli Lilly had a molecule in hand. Understanding that origin tells you why tirzepatide works differently from every GLP-1 drug that came before it.

The incretin hypothesis and the two gut hormones

In the 1980s and 1990s, researchers studying postprandial glucose control identified two peptide hormones released from the gut after eating: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Both stimulate insulin secretion in a glucose-dependent fashion, meaning they amplify the insulin response only when blood sugar is already rising. Early work showed that GLP-1 receptor activation reduces appetite, slows gastric emptying, and suppresses glucagon, making it an attractive drug target. GIP was considered less commercially interesting for years because early studies suggested it lost its insulin-stimulating effect in established type 2 diabetes.

That GIP finding led most of the pharmaceutical industry to focus on GLP-1 alone. Liraglutide (Victoza, 2010) and semaglutide (Ozempic, 2017) followed that single-agonist logic.

Lilly's decision to target both receptors

Eli Lilly researchers took a different path. Internal preclinical work and a growing body of academic literature suggested that GIP's apparent failure in type 2 diabetes might reflect the specific conditions of those studies rather than a true pharmacological limitation. Rodent models showed that co-activation of both GIP and GLP-1 receptors produced additive effects on weight loss and glycemia that neither agonist produced alone. The mechanistic rationale: GIP receptor activation in adipose tissue and the central nervous system may complement GLP-1-mediated satiety signaling through distinct downstream pathways.

Lilly's medicinal chemistry team set out to design a single peptide molecule that could bind both receptors with meaningful potency, while remaining stable enough for once-weekly dosing. The solution was a 39-amino-acid synthetic peptide built on a GIP backbone, with a fatty-acid moiety attached via a linker to extend half-life through albumin binding. This structure allows tirzepatide to achieve a plasma half-life of approximately 5 days, which supports weekly injection without the daily dosing required by earlier incretin agents.

Early-phase clinical work

Phase 1 studies established tirzepatide's pharmacokinetic profile and confirmed that the dual-receptor approach was tolerable in humans. Phase 2 data, published between 2018 and 2020, showed dose-dependent reductions in A1C and body weight that exceeded what had been observed with GLP-1 monotherapy at comparable doses. These results justified the large SURPASS phase 3 program.

The SURPASS Trial Program: What the Evidence Actually Shows

The SURPASS series (SURPASS-1 through SURPASS-6, plus SURPASS-CVOT) was a global phase 3 program designed to evaluate tirzepatide across multiple comparators and patient populations. For women, the most immediately relevant results come from SURPASS-2 and the body-weight sub-analyses.

SURPASS-2: Tirzepatide versus semaglutide 1 mg

SURPASS-2, published in the New England Journal of Medicine in 2021, randomized 1,879 adults with type 2 diabetes inadequately controlled on metformin to tirzepatide 5 mg, 10 mg, or 15 mg once weekly, or semaglutide 1 mg once weekly, for 40 weeks. All three tirzepatide doses achieved statistically superior A1C reduction and weight loss compared with semaglutide 1 mg. The 15 mg tirzepatide arm reduced A1C by a mean of 2.3 percentage points from a baseline of approximately 8.3%, versus 1.86 percentage points with semaglutide. Body weight fell by 12.4 kg with tirzepatide 15 mg versus 6.2 kg with semaglutide 1 mg.

Roughly 46% of the SURPASS-2 participants were women. The sex-stratified sub-analyses were not the primary endpoint, and women-specific data from this trial remain limited to supplementary tables rather than dedicated publications, which reflects a broader gap in sex-disaggregated reporting in diabetes trials (see rule W6 below).

SURMOUNT: Tirzepatide for obesity without diabetes

The SURMOUNT-1 trial enrolled adults with obesity (body mass index >30 kg/m²) or overweight (body mass index >27 kg/m²) plus at least one weight-related complication, without type 2 diabetes. At 72 weeks, tirzepatide 15 mg produced a mean weight reduction of 22.5% from baseline, a magnitude not previously seen in a pharmacological obesity trial. Women made up approximately 67% of the SURMOUNT-1 population, and the average baseline weight was 104.8 kg. This female-majority enrollment makes SURMOUNT-1 the most directly applicable large-scale evidence base for most women reading this article.

What trials have not shown yet

No dedicated tirzepatide trial has enrolled women with PCOS as the primary population. No randomized data exist specifically in perimenopause or postmenopause. The SURPASS-CVOT trial (cardiovascular outcomes) is ongoing. Data in pregnancy, lactation, and adolescent females are absent from the published record.

The WomanRx clinical framework below organizes what is known, what is extrapolated, and what is absent for women at each life stage, because conflating all three categories is how misinformation spreads.

| Life Stage | Direct Tirzepatide Evidence | Extrapolated from Broader Data | No Data | |---|---|---|---| | Reproductive years / PCOS | Case series, mechanistic rationale | GLP-1 effects on hyperandrogenism | Dedicated RCT | | Trying to conceive | None | Teratogenicity concern from rodent data | Human pregnancy outcomes | | Pregnancy | Contraindicated | Rodent embryofetal toxicity | Human safety | | Postpartum / lactation | None | Unknown transfer risk | Breast milk levels | | Perimenopause | None | Metabolic benefit in insulin resistance | Interaction with HRT | | Post-menopause | None | Weight and glycemia benefits from SURMOUNT | Bone, cardiovascular co-data with HRT |

How Tirzepatide Works: The Mechanism in Plain Terms

Tirzepatide acts at two receptors simultaneously: GIP receptors and GLP-1 receptors. This dual action is what separates it from every other approved incretin drug.

GLP-1 receptor activation

When tirzepatide binds GLP-1 receptors in the pancreas, it stimulates insulin secretion in proportion to ambient glucose. This is the same pathway exploited by semaglutide and liraglutide. GLP-1 receptor activation also slows gastric emptying and signals satiety through vagal afferents and hypothalamic circuits, which is the primary mechanism behind appetite reduction and weight loss.

GIP receptor activation: the added layer

GIP receptors are expressed in adipose tissue, bone, the gut, and the central nervous system. In metabolically healthy individuals, GIP amplifies the postprandial insulin response. In people with type 2 diabetes, this amplification is blunted, which led to early dismissal of GIP as a drug target. Tirzepatide appears to overcome this blunting through receptor binding kinetics that differ from native GIP. Animal and early human data suggest that GIP receptor co-activation may enhance fat utilization in adipose tissue and further reduce food intake through central mechanisms that are distinct from GLP-1 pathways.

The net result: tirzepatide produces weight loss and glycemic improvement that is, at approved doses, numerically larger than what is seen with GLP-1 monotherapy.

Sex-specific pharmacokinetics

Body weight, fat mass distribution, and hormonal status all influence how incretin drugs behave. Women typically carry a higher proportion of subcutaneous fat relative to visceral fat compared with men, which affects both drug distribution after subcutaneous injection and the downstream metabolic response to GIP receptor activation in adipose tissue. Pharmacokinetic analyses of GLP-1 receptor agonists consistently show lower exposure in higher-weight individuals, which is relevant because dose titration targets in the tirzepatide label are based on efficacy and tolerability rather than weight-adjusted dosing. Menstrual cycle phase and estrogen status may modulate GLP-1 receptor expression in the gut and brain, though direct tirzepatide PK data stratified by cycle phase do not yet exist in the published literature.

FDA Approval: The Regulatory Path

Eli Lilly submitted the New Drug Application for tirzepatide in October 2021. The FDA granted priority review, and Mounjaro received full approval on May 13, 2022 for adults with type 2 diabetes as an adjunct to diet and exercise. The approved doses are 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, with a standard titration starting at 2.5 mg weekly for four weeks before stepping up.

In November 2023, the FDA approved Zepbound, the same tirzepatide molecule at the same doses, specifically for chronic weight management in adults with obesity or overweight plus a weight-related condition. The distinction between Mounjaro and Zepbound is regulatory labeling and sometimes insurance coverage, not pharmacology.

Tirzepatide and Women-Specific Conditions

PCOS

Polycystic ovary syndrome affects approximately 8-13% of reproductive-age women worldwide and is characterized by hyperinsulinemia, insulin resistance, androgen excess, and disordered ovulation. GLP-1 receptor agonists, including liraglutide and semaglutide, have been studied in small trials for PCOS and show reductions in weight, fasting insulin, and androgen levels. No randomized controlled trial of tirzepatide has enrolled women with PCOS as the primary diagnosis. The mechanistic case for tirzepatide in PCOS is strong: dual GIP plus GLP-1 activity may address the hyperinsulinemia-driven androgen excess more effectively than GLP-1 alone, but this remains an extrapolation from mechanism and from GLP-1 monotherapy data rather than a tirzepatide-specific finding.

If you have PCOS and are considering tirzepatide, the absence of PCOS-specific trial data means benefits and risk calibration should be discussed with a clinician who knows your full hormonal picture, including whether you are also using combined oral contraceptives for cycle regulation, since GLP-1 receptor agonists alter gastric emptying in a way that could theoretically reduce oral contraceptive absorption during the first few weeks of treatment.

Perimenopause and post-menopause

The menopausal transition brings a shift toward central adiposity, worsening insulin sensitivity, and increased cardiovascular risk. GLP-1 receptor agonists are not contraindicated with menopausal hormone therapy and no known pharmacokinetic interaction exists between tirzepatide and estrogen or progesterone. However, dedicated data on tirzepatide in postmenopausal women, specifically around bone density (GIP receptors are expressed in osteoblasts), cardiovascular benefit, and interaction with systemic hormone therapy, have not been published. The ongoing SURPASS-CVOT trial will provide some cardiovascular outcome data, though postmenopausal subgroup analyses are not guaranteed.

Female pattern metabolic disease

Women with type 2 diabetes have a disproportionately higher relative cardiovascular risk compared with their male counterparts. A 2014 meta-analysis in the Lancet found that women with diabetes carry a 44% greater excess risk of coronary heart disease death than men with diabetes. This sex-specific risk amplification makes effective glycemic and weight management drugs particularly consequential for women, and it is one reason the female-majority enrollment in SURMOUNT-1 matters.

Pregnancy, Lactation, and Contraception: What You Must Know

Tirzepatide is contraindicated in pregnancy. Full stop.

If you could become pregnant and are taking tirzepatide, you need reliable contraception throughout treatment.

Pregnancy category and human data

The FDA has not assigned a letter category under the old system; tirzepatide was approved under the 2015 labeling rule that requires narrative risk summaries. The Mounjaro prescribing information states that animal studies at exposures below the maximum recommended human dose showed embryofetal toxicity, including skeletal anomalies, in rats and rabbits. No adequate human pregnancy studies exist. Because of the animal signal and the absence of human safety data, Lilly and the FDA advise discontinuing tirzepatide at least 2 months before a planned pregnancy, based on the drug's approximately 5-day half-life and the conservative five-half-life washout window.

If you become pregnant while taking tirzepatide, contact your prescriber immediately. Pregnant women taking tirzepatide inadvertently may be enrolled in the Mounjaro Pregnancy Registry by calling 1-800-545-5979.

Lactation

Tirzepatide has not been detected or quantified in human breast milk in any published study. The prescribing information advises against use during breastfeeding due to the absence of data on drug transfer, effects on the breastfed infant, or effects on milk production. Given tirzepatide's molecular weight and albumin-binding properties, meaningful transfer into milk is considered unlikely by some pharmacologists, but "unlikely" is not "proven safe," and a newborn's metabolic systems cannot be considered equivalent to an adult's.

Contraception considerations

Women of reproductive age who are prescribed tirzepatide and rely on oral contraceptives should be aware that GLP-1 receptor agonists slow gastric emptying, which may reduce the rate (not necessarily the extent) of oral contraceptive absorption during initial weeks of use. Lilly's label recommends switching to a non-oral contraceptive method, or adding a barrier method, for four weeks after starting tirzepatide and for four weeks after each dose escalation. Intrauterine devices and progestin implants are not affected by gastric emptying and are straightforward alternatives.

Who Mounjaro Is Right For, and Who Should Wait

More likely to benefit

• Women with type 2 diabetes not adequately controlled on metformin alone or metformin plus another agent
• Women with obesity (body mass index >30 kg/m²) or overweight (body mass index >27 kg/m²) with a related condition such as hypertension, obstructive sleep apnea, or dyslipidemia, when prescribed as Zepbound
• Women with PCOS-associated insulin resistance and obesity, acknowledging the extrapolation from GLP-1 monotherapy evidence
• Postmenopausal women with type 2 diabetes or metabolic syndrome who have not responded adequately to lifestyle intervention

Not the right choice right now

• Women who are pregnant, planning pregnancy within two months, or breastfeeding
• Women with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (a class contraindication shared with all GLP-1 receptor agonists)
• Women with a history of severe or recurrent pancreatitis
• Women who have not tried structured lifestyle modification, since tirzepatide works best as an adjunct to, not a replacement for, dietary and behavioral change

The Evidence Gap: What Trials Have Not Told Us

Dr. Elena Vasquez, MD, WomanRx reproductive endocrinologist and article reviewer, notes: "The SURMOUNT and SURPASS programs enrolled enough women to generate meaningful average results, but sex-stratified analyses and life-stage-specific subgroups, particularly women in perimenopause and women with PCOS, were not pre-specified primary endpoints. Until that granular data is published or dedicated trials are run, we are doing clinical extrapolation for a substantial portion of our female patients."

This gap is not unique to tirzepatide. Women have historically been underrepresented in cardiometabolic drug trials, and even when enrolled in similar numbers, subgroup analyses by hormonal status, menstrual phase, or reproductive stage are rarely performed. The SURPASS-2 trial included approximately 46% women but did not publish sex-disaggregated efficacy or safety results as a primary analysis. Demanding better from trial design is appropriate and overdue.